Supported by an educational grant from Geron

Click on the link to complete the pre-assessment questions before the session begins: https://mli.link/sohomdspre

SESSION II: MYELODYSPLASTIC SYNDROMES

Session Chairs: Guillermo Garcia-Manero, MD and Valeria Santini, MD

Molecular and Cellular Basis of MDS | Jaroslaw Maciejewski, MD, PhD | Cleveland Clinic, Cleveland, Ohio, USA

Therapeutic Advances in Lower-Risk MDS | Valeria Santini, MD | University of Florence, Florence, Italy

Higher-Risk MDS in 2025 | Amy E. DeZern, MD, MHS | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Transplantation for Myelodysplastic Syndromes | Uday R. Popat, MD | MD Anderson Cancer Center, Houston, Texas, USA

AI Approaches in MDS | Matteo Della Porta, MD | Humanitas Research Hospital, Milan, Italy

Oral Abstract | MDS-1497: Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes | Guillermo Garcia-Manero, MD | MD Anderson Cancer Center, Houston, Texas, USA